Jones Day (Washington DC)

Geoffrey D. Oliver

Jones Day (Washington DC)
Lawyer (Partner)

Geoffrey Oliver is partner at Jones Day (Washington). His practice focuses on antitrust matters, with emphasis on government merger and conduct investigations and on litigation and counseling with respect to matters involving antitrust and patent law. He counsels high-tech and manufacturing companies in the computer, semiconductor, consumer electronics, satellite, defense, pharmaceutical, health care, and medical devices industries. Mr. Oliver co-coordinates the firm’s practice involving application of antitrust law to issues involving intellectual property. From 1998 to 2007, Mr. Oliver held various positions in the Federal Trade Commission’s Bureau of Competition, including Assistant Director responsible for the Anticompetitive Practices Division. During his tenure at the FTC, he supervised numerous nonpublic investigations and litigated cases in both the FTC’s Part III administrative proceedings and federal court. He was lead counsel on In re Rambus Inc. and played substantial roles on litigation teams for In re Hoechst Marion Roussel, Inc. et al., In re Intel Corp., and FTC v. Tenet Healthcare Corp. In addition to his enforcement responsibilities at the FTC, he participated in various policy initiatives involving standard-setting, intellectual property, and other issues. Before joining the FTC, Mr. Oliver spent ten years in private practice in Washington, D.C. and Brussels, Belgium. Mr. Oliver has written on antitrust enforcement topics and has spoken on antitrust and intellectual property issues in the United States and abroad. He currently serves on the board of editors of the ABA’s Antitrust magazine.

Distinctions

Linked authors

Jones Day (London)
Jones Day (Washington DC)
Jones Day (Washington DC)
Jones Day (Cleveland)
Jones Day (Beijing)

Articles

6484 Bulletin

Peter J. Wang, Yizhe Zhang, Qiang Xue, Geoffrey D. Oliver, Alexandre G. Verheyden, Haifeng Huang The Chinese State Administration for Market Regulation publishes anti-monopoly guidelines on intellectual property

28

In August 2020, the Anti-Monopoly Bureau of China’s State Administration for Market Regulation released four long-awaited sets of anti-monopoly guidelines addressing issues relating to leniency, commitments, the automobile industry, and intellectual property rights. The subjects of this White (...)

Geoffrey D. Oliver, Paula W. Render, Pamela L. Taylor, Kristie Xian The US Court of Appeals for the Seventh Circuit denies the FTC’s authority to seek restitution (Credit Bureau)

94

In Short The Situation: Overruling its precedent, the United States Court of Appeals for the Seventh Circuit held that the Federal Trade Commission ("FTC") may not seek restitution under FTC Act Section 13(b) because the statute, which permits the FTC to obtain injunctions, does not explicitly (...)

Geoffrey D. Oliver, Kathryn M. Fenton, Matt Evans, Michelle K. Fischer, Peter J. Wang The US FTC and DOJ publish the proposed antitrust guidelines for international enforcement and cooperation

200

The Federal Trade Commission and the Department of Justice have published for public comment proposed Antitrust Guidelines for International Enforcement and Cooperation ("2016 Proposed Guidelines"). This would be the third iteration of international enforcement guidelines, following the (...)

Bevin M.B. Newman, Geoffrey D. Oliver, Michael Sennett The Court of Appeal for the District of Columbia rejects a challenge to an FTC rule that makes the HSR Act reporting requirements cover pharmaceutical patent licenses that transfer all commercially significant rights (PhRMA)

187

The D.C. Circuit has rejected a challenge by the Pharmaceutical Research and Manufacturers of America ("PhRMA") to an FTC rule that makes the HSR Act reporting requirements cover pharmaceutical patent licenses that transfer "all commercially significant rights." The rule, adopted in 2013, (...)

Geoffrey D. Oliver, Kevin D. McDonald, Michelle K. Fischer The U.S. Court of Appeals for the Federal Circuit renders a split decision regarding sham patent litigation (Tyco Healthcare / Mutual Pharmaceutical)

146

The U.S. Court of Appeals for the Federal Circuit has remanded for further consideration antitrust claims accusing a patent holder of filing a sham infringement suit and a sham citizen petition with the Federal Drug Administration. The case is Tyco Healthcare Group LP v. Mutual Pharmaceutical (...)

Craig A. Waldman, David P. Wales, Geoffrey D. Oliver The US FTC announces an unusual proposed consent agreement to resolve unprecedented allegations on enforcement of standards-essential patents (Bosch / SPX)

468

The U.S. Federal Trade Commission this week announced a highly unusual proposed consent agreement reached with Robert Bosch GmbH ("Bosch") that permits Bosch’s acquisition of SPX Service Solutions U.S. LLC ("SPX Service Solutions") from SPX Corporation ("SPX") to proceed. More significantly, it (...)

David P. Wales, Geoffrey D. Oliver, Michael H. Knight The US FTC sues to undo completed acquisition in the healthcare industry approved by bankruptcy court (LabCorp / Westcliff)

548

The Federal Trade Commission has filed an administrative lawsuit seeking to undo Laboratory Corporation of America’s (« LabCorp ») acquisition of Westcliff Medical Laboratories, Inc. (« Westcliff »). According to the agency’s December 1 complaint, the merger will substantially lessen competition (...)

David P. Wales, Geoffrey D. Oliver, Michael H. Knight The US FTC sues to undo completed acquisition in the healthcare industry approved by the Bankruptcy Court (LabCorp / Westcliff)

149

The Federal Trade Commission has filed an administrative lawsuit seeking to undo Laboratory Corporation of America’s (« LabCorp ») acquisition of Westcliff Medical Laboratories, Inc. (« Westcliff »). According to the agency’s December 1 complaint, the merger will substantially lessen competition (...)

Geoffrey D. Oliver, Michael H. Knight, Toby G. Singer The US District Court for the District of Minnesota dismisses the US FTC complaint seeking divestiture and disgorgement remedy in consummated acquisition in the healthcare industry (Lundbeck)

1277

In a decision that was filed under seal in late August but released publicly just last week, the U.S. District Court for the District of Minnesota dismissed with prejudice the complaint filed by the Federal Trade Commission (FTC) and the State of Minnesota challenging the already-consummated (...)

David Maiorana, Geoffrey D. Oliver, Kenneth R. Adamo, Michelle K. Fischer The US Court of Appeals for the Federal Circuit limits patent misuse doctrine and distinguishes it from antitrust violation (Princo)

1079

The U.S. Court of Appeals for the Federal Circuit issued an en banc decision with significant implications for the doctrine of patent misuse. The decision issued last week overturns part of a Federal Circuit panel decision last year holding that Philips may have committed patent misuse by (...)

6815 Review

Assimakis Komninos, Florence Ninane, Francesco Rosati, Geoffrey D. Oliver, Hendrik Bourgeois, Ioannis Lianos, James Killick, Johanne Peyre, Niamh McCarthy, Philippe Choné The EU guidance on exclusionary abuses: A step forward or a missed opportunity?

6815

What are the consequences for business of the Commission’s Communication on Article 82 of the Treaty? Does it make the Commission’s action more predictable? Does the use of a wide range of economic criteria reduce the risk that pro-competitive practices by dominant companies will be considered (...)

Send a message